2019-07-29 Source
On July 27, 2019, the First Joint Conference of the Management Committee and Academic Committee(hereinafter referred to as the “Joint Conference”) of “Hepatology fund of TCM and Western Medicine ” solely sponsored by Beijing Han Dian Pharmaceutical Company was held in Beijing. Mr. Lin Deliang, the chairman of the Group, Mr. Yang Chuanjun, the general manager of Beijing Han Dian Pharmaceutical Company and Beijing Red Sun Pharmaceutical Company, Mr. Xie Fuping, the general manager of liver disease business department, attended the meeting.
The conference was co-chaired by Prof. Yang Xizhong, who is executive vice president and secretary-general of Chinese Foundation for Hepatitis Prevention and Control, director of the Fund Management Committee, and Prof. Duan Zhongping, vice president of Beijing You'an Hospital Affiliated to Capital Medical University and member of the Fund Advisory Committee. Prof. Zhuang Hui, academician of Chinese Academy of Engineering and Medical Department of Peking University, Prof. Wang Lingtai, former president of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Prof. Wu Shanming, former president of Shanghai Public Health Clinical Center, and Pro. Ye Yong'an, secretary of the Party Committee of Dongzhimen Hospital of Beijing University of Traditional Chinese Medicine attended the conference and guided the work. Prof. Xu Xiaoyuan, the chairman of Chinese Society of Hepatology of Chinese Medical Association(CMA), the First Hospital of Peking University, Prof. Li Xiuhui, the chairman of Chinese Society of Hepatology of CMA, Beijing You'an Hospital Affiliated to Capital Medical University, and 44 experts in hepatology from Chinese and Western medicine attended the conference and discussed their work.
Prof. Yang Xizhong first introduced the implementation of the project to the participating experts. He pointed out that the Fund is mainly used to support clinical training and project research of liver disease doctors in Chinese and Western medicine. The clinical training of liver diseases in Chinese and Western medicine must adhere to the principle of attaching equal importance to both Chinese and Western medicine, the combination of clinical application and scientific research, the combination of popularization and improvement, and the cultivation of basic theories of Chinese and Western medicine, clinical thinking and skills; the establishment and selection of scientific research projects must adhere to the principle of public welfare, openness, fairness, equity, standardization and transparency, and the principle of focusing on clinical application research in Chinese and Western medicine and pay attention to the practicability of the project. The Fund establishes an organizational structure, an advisory committee, a management committee and an academic committee to carry out scientific management of the Fund, ensuring the active implementation of training and the quality of research projects. As core members of the Foundation, all the experts present at the conference should give full play to the leading role of the discipline to ensure the smooth development of the project. At the same time, great appreciate should be given to Beijing Han Dian Pharmaceutical Company for its support for this project.
After the letter of appointment was issued to all members of the organization, Prof. Xu Xiaoyuan and Prof. Li Xiuhui, the directors of the academic committee of the foundation, respectively led the experts attending the meeting around the following documents, including the Management Measures of Fund of Liver Disease Treated by TCM and Western Medicine (Trial), the Detailed Rules for the Management of Clinical Doctor Training of Fund of Liver Disease Treated by TCM and Western Medicine(Trial), and the Detailed Rules for the Management of Scientific Research Projects of Fund of Liver Disease Treated by TCM and Western Medicine (Trial), etc. They conducted an in-depth discussion and revision. Then, the Academician Zhuang Hui concluded the meeting and discussed: First, the purpose of the Foundation is to improve the level of diagnosis and treatment of liver diseases in TCM and Western medicine, advance the ability of scientific research and design, and develop both training and scientific research. Second, with limited funds, training and scientific research should be allocated in an appropriate manner to focus on the small but precise projects. Third, the application must study the subject of the integration of TCM and Western medicine. Fourth, experts of the Committee should vigorously publicize the project, encourage doctors to actively participate in the project, and ensure the quality of the project. Mr. Lin Deliang, the chairman of Han Dian Group, delivered a speech on behalf of the company: TCM boasts its unique advantages and value. The treatment of chronic hepatitis B with TCM therapy is an indispensable clinical treatment. As one of the top 100 Chinese medicinal enterprises, Beijing Han Dian Pharmaceutical Co., Ltd. will shoulder the mission of serving the whole people's health, gather the strength of the top liver expert team, and benefit more patients with chronic hepatitis B. Finally, Minister Yang Xizhong said that the Fund has strengthened its academic strength with the support of experts. In the process of running the Fund, we should do what we can to find out and fill in the gaps, and stick to supporting small but precise clinical topics, so as to jointly promote the development of TCM and Western medicine and serve more patients.
After the Joint Conference, Prof. Xu Xiaoyuan, Prof. Li Xiuhui and other experts continued the Ziyedan Academic Seminar. Ms. Huang Hui, director of research and development of Medicine (Toxicology) Department of Han Dian Research Institute, and Prof. Sun Kewei, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, respectively made brief reports on the basic research and the phase III and phase IV clinical research of Ziyedan. Prof. Gao Yueqiu, vice president of Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, reported the latest research results of Ziyedan on some patients with chronic hepatitis B. The results showed that the combination of Ziyedan and entecavir could further promote the negative conversion of HBeAg, compaired with using entecavir alone. Prof. Wang Lingtai affirmed the scientific rationality of Ziyedan formula. Based on the fomula and the analysis of the research results, the following conclusions can be drawn: Ziyedan is suitable for patients with low virus level, poor immune response, and those who need consolidation treatment after drug withdrawal.. In addition, the selection of targeted patients and research direction of Ziyedan in the future were suggested. Prof. Wu Shanming explained and shared how to select patients during the clinical practical application of Ziyedan in combination with his own medication experience. In one case, HBsAg remained unchanged in more than 500 units after 1-2 years of nucleoside combined with interferon therapy, but decreased to more than 300 units after adding Ziyedan for one month, which provided a new direction for the exploration of clinical medication of Ziyedan. Director Li Xiuhui concluded the Ziyedan Academic Seminar, affirmed the prescription and advantages of Ziyedan. She shared the anti-fibrosis study of Ziyedan, with the results showed that Ziyedan had certain efficacy in reversing fibrosis. Li suggested a further in-depth study to improve the research level. At the same time, the applicable population of Ziyedan was summarized, and different courses of treatment were suggested according to different treatment goals. So far, the First Joint Conference of the Management Committee and Academic Committee of Hepatology fund of TCM and Western Medicine and Ziyedan Academic Seminar have come to a successful conclusion!
Supported exclusively by Han Dian Group, the “Fund of Liver Diseases Treated by TCM and Western Medicine” initiated by the Foundation of Liver Diseases is the fifth fund established by the Foundation in the past 20 years and the first fund in the field of TCM. Through the platform of this Fund, the Department of Liver Disease has also created a top team of liver disease experts belonging to Ziyedan, helping the cause of liver disease take off as soon as possible!
Prev: the Establishment Conference of the Expert Committee of Grassroots Feasible Technology Co-organized By Beijing Han Dian Pharmaceutical Company Came to a Successful Conclusion
Next: Han Dian Pharmaceutical Company has Won the Title of “Top 100 Brand Enterprises of Chinese National Medicine” for Three Consecutive Years